Janus Henderson Group PLC Sells 548,880 Shares of Inspire Medical Systems, Inc. $INSP

Janus Henderson Group PLC trimmed its holdings in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 97.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,451 shares of the company’s stock after selling 548,880 shares during the quarter. Janus Henderson Group PLC’s holdings in Inspire Medical Systems were worth $694,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. CWM LLC lifted its position in shares of Inspire Medical Systems by 216.1% during the fourth quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after purchasing an additional 242 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Inspire Medical Systems by 1,115.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock worth $33,000 after buying an additional 580 shares during the last quarter. Havemeyer Place LP bought a new position in shares of Inspire Medical Systems during the 4th quarter worth approximately $39,000. V Square Quantitative Management LLC bought a new position in shares of Inspire Medical Systems during the 4th quarter worth approximately $40,000. Finally, Smartleaf Asset Management LLC lifted its position in Inspire Medical Systems by 84.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after acquiring an additional 205 shares during the last quarter. 94.91% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

INSP has been the topic of a number of recent analyst reports. Evercore set a $54.00 price target on Inspire Medical Systems in a research report on Tuesday, August 4th. Freedom Capital upgraded Inspire Medical Systems to a “strong-buy” rating in a research note on Tuesday, June 30th. UBS Group began coverage on Inspire Medical Systems in a research report on Tuesday, July 28th. They set a “sell” rating and a $39.00 target price on the stock. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $60.00 price target on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Finally, KeyCorp reissued a “sector weight” rating on shares of Inspire Medical Systems in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $68.00.

Inspire Medical Systems Stock Down 0.5%

Shares of NYSE:INSP opened at $59.84 on Tuesday. Inspire Medical Systems, Inc. has a 52-week low of $38.91 and a 52-week high of $147.03. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of 12.95, a PEG ratio of 4.57 and a beta of 0.70. The business has a 50-day moving average price of $48.02 and a 200-day moving average price of $54.01.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, August 3rd. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The firm had revenue of $200.58 million for the quarter, compared to analyst estimates of $194.72 million. During the same quarter in the prior year, the firm earned $0.45 earnings per share. Inspire Medical Systems’s revenue for the quarter was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, equities analysts anticipate that Inspire Medical Systems, Inc. will post 1.24 EPS for the current fiscal year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.